Eagle Asset Management Inc Adma Biologics, Inc. Transaction History

Eagle Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$3.08 - $4.52 $13,450 - $19,738	4,367 Added 20.23%	25,957 $117,000
Q2 2023 Aug 09, 2023	BUY	$3.12 - $4.22 $6,917 - $9,355	2,217 Added 11.44%	21,590 $79,000
Q1 2023 May 08, 2023	BUY	$3.01 - $3.87 $19,697 - $25,325	6,544 Added 51.01%	19,373 $64,000
Q4 2022 Feb 14, 2023	BUY	$2.47 - $3.88 $31,687 - $49,776	12,829 New	12,829 $49,000
Q1 2022 May 12, 2022	BUY	$1.28 - $1.83 $13,159 - $18,814	10,281 Added 55.42%	28,833 $52,000
Q1 2021 May 14, 2021	BUY	$1.67 - $2.95 $3,857 - $6,814	2,310 Added 14.22%	18,552 $33,000
Q4 2020 Feb 12, 2021	BUY	$1.8 - $2.56 $10,422 - $14,822	5,790 Added 55.4%	16,242 $31,000
Q3 2020 Nov 12, 2020	BUY	$2.04 - $3.74 $21,322 - $39,090	10,452 New	10,452 $22,000

312

184M

917K

91.6K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.16B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.